Usual Adult Dose for Chronic Hepatitis C:
400 mg orally once a day
Recommended Regimen and Duration of Therapy:
-Genotype 1 or 4: Sofosbuvir, peginterferon alfa, and ribavirin for 12 weeks
-Genotype 2: Sofosbuvir and ribavirin for 12 weeks
-Genotype 3: Sofosbuvir and ribavirin for 24 weeks
-Hepatocellular carcinoma awaiting liver transplantation: Sofosbuvir and ribavirin for up to 48 weeks or until liver transplantation (whichever occurs first)
Comments:
-Genotype 1, 4: This regimen is recommended for therapy-naive patients without cirrhosis or with compensated cirrhosis (Child-Pugh A).
-Genotype 2, 3: Both regimens are recommended for therapy-naive and therapy-experienced patients without cirrhosis or with compensated cirrhosis (Child-Pugh A).
-Therapy-experienced patients have failed an interferon-based regimen (with or without ribavirin).
-The dose recommendations for genotype 1, 2, 3, or 4 should be followed for HCV/HIV-1-coinfected patients.
-The manufacturer product information should be consulted for ribavirin tablet dose recommendations; with genotype 1 or 4, the manufacturer product information for peginterferon alfa should also be consulted for dose recommendations.
-Sofosbuvir and ribavirin for 24 weeks can be considered for patients with genotype 1 infection who cannot use an interferon-based regimen; treatment decision should be guided by benefit/risk assessment for the individual patient.
-The regimen for patients with hepatocellular carcinoma awaiting liver transplantation is recommended to prevent posttransplant HCV reinfection.
Use: As a part of a combination antiviral treatment regimen, for the treatment of chronic HCV infection
-In combination with pegylated interferon and ribavirin: For genotype 1 or 4 infection without cirrhosis or with compensated cirrhosis
-In combination with ribavirin: For genotype 2 or 3 infection without cirrhosis or with compensated cirrhosis
Usual Pediatric Dose for Chronic Hepatitis C:
3 years or older:
-Weight less than 17 kg: 150 mg orally once a day
-Weight 17 to less than 35 kg: 200 mg orally once a day
-Weight at least 35 kg: 400 mg orally once a day
Recommended Regimen and Duration of Therapy:
-Genotype 2: Sofosbuvir and ribavirin for 12 weeks
-Genotype 3: Sofosbuvir and ribavirin for 24 weeks
-Hepatocellular carcinoma awaiting liver transplantation: Sofosbuvir and ribavirin for up to 48 weeks or until liver transplantation (whichever occurs first)
Comments:
-Both regimens are recommended for therapy-naive and therapy-experienced patients without cirrhosis or with compensated cirrhosis (Child-Pugh A).
-Therapy-experienced patients have failed an interferon-based regimen (with or without ribavirin).
-The manufacturer product information should be consulted for ribavirin dose recommendations.
-The same dose recommendations should be followed for HCV/HIV-1-coinfected patients.
-The regimen for patients with hepatocellular carcinoma awaiting liver transplantation is recommended to prevent posttransplant HCV reinfection.
Use: In combination with ribavirin, for the treatment of chronic HCV genotype 2 or 3 infection in patients without cirrhosis or with compensated cirrhosis
 Detailed Sofosbuvir dosage information
What happens if I miss a dose?
Take the medicine as soon as you can, but skip the missed dose if it is almost time for your next dose. Do not take two doses at one time.
Get your prescription refilled before you run out of medicine completely.
What happens if I overdose?
Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.
